GlaxoSmithKline PLC — Director's Dealing 2016

Oct 17, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7590M

GlaxoSmithKline PLC

17 October 2016

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	447.196

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	223.598

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
$42.0900	284.061

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

Senior Vice President, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, Pharmaceuticals R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.  

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	223.598

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDDLFFQBFLFBQ

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'aB3c1_I9TalKMNbIXAfa05CI3s0Xu_9lkPWjLj0LuoL7Vi76XzLIn6BHYuM0hk7n2qiir0_o1iL4pHBmeGxg4IRg2hzh5xvF0ZrGZ7ogKu41:pYB82pFJ9JvkdIxd-HRZsUgwANb0yXAMGO1pMaO2QZd5t7fUHchdzWSrVcU-afDpNUyZw03h9NyJ72JybQK8GqR57oCQnwZ4krJ5Y6P4_vg1'}});//]]>